Skip to main content

Study

MM120 Psychedelic Treatment Reduces Anxiety in Adults

Clinical trial finds psychedelic therapy may reduce anxiety, but older adults were underrepresented.

Mental WellnessStress & Anxiety
Study Credibility: Medium5.6/10Some supporting evidenceStudy has limitationsUse with caution
PublishedSep 2025Last reviewedMar 2026
Email this

Summary

In plain language

This JAMA-published study tested different doses of MM120 (25–200 µg) in 198 adults with generalized anxiety disorder. The 100 µg and 200 µg doses led to meaningful reductions in anxiety symptoms over 4 weeks. Side effects were dose-dependent and included visual changes and nausea. While well-conducted, the study underrepresented older adults and hasn't yet been replicated.

Details

Use the full description to understand the study design, methods, and the limits of the findings.

This clinical research demonstrates that MM120, a psychedelic compound, significantly reduces anxiety in adults. The study reports on treatment protocols, safety profiles, and sustained anxiety reduction following controlled administration of this investigational therapy.

Research Quality Score

Scored March 23, 2026 using rubric v8_2026-03-10.

Assessment

The study is a well-conducted clinical trial published in a reputable journal, but it lacks detailed methodological transparency and has not been replicated. Its relevance to seniors is limited due to underrepresentation of older adults.

Category Breakdown

CategoryScoreRating
Study design6.7/10
Bias control6.7/10
Statistical methods5.0/10
Reporting completeness5.0/10
Conflicts & funding5.0/10
Replication0.0/10
Relevance to chosen population0.0/10
Journal Reliability10.0/10

Additional Notes

The study's focus on a novel treatment for anxiety is promising, but further replication and detailed methodological transparency are needed for stronger validation.

Take the next step

Build a personalized plan using research-backed studies, conditions, and treatments.